Cologuard Available to Humana Members as In-Network Colon Cancer Screening Option
Hawaii News Now,
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
SOURCE EXACT SCIENCES CORP Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening…
Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening Test and Compliance Service…
MADISON, Wis., Dec. 12, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed…
MADISON, Wis., Dec. 12, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed…
Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening Test and Compliance Service…
MADISON, Wis., Dec. 12, 2016 /PRNewswire/ -- Exact Sciences Corp. (EXAS) announced today that under a recently-signed contract…
MADISON, Wis. "As demand for Cologuard grows, this contract marks an opportunity to increase access to colon cancer screening…
MADISON, Wis., Dec. 12, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq:EXAS) announced today that under a recently-signed…
Members of Fifth Largest Commercial Insurer will have Access to Non-Invasive Colon Cancer Screening Test and Compliance Service…
MADISON, Wis., Dec. 12, 2016 /PRNewswire/ -- Exact Sciences Corp. ( EXAS ) announced today that under a recently-signed contract…
MADISON, Wis., Dec. 12, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed…
MADISON, Wis., Dec. 12, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed…
MADISON, Wis., Dec. 12, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed…
As reviewed in this issue of The ASCO Post, the U.S. Preventive Services Task Force (USPSTF) recently updated its guidelines…
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has issued new recommendations for colorectal cancer…
Exact Sciences has been trading higher on a predictable sales beat in Q2 and a positive decision from the USPSTF whereby "colorec…
Return to Article List Next Article > Released: 15-Aug-2016 3:05 PM EDT Source Newsroom: American College of Radiology (ACR…
WASHINGTON, Aug. 15, 2016 /PRNewswire-USNewswire/ — Colorectal cancer patient advocacy groups, the American College of…
WASHINGTON, Aug. 15, 2016 /PRNewswire-USNewswire/ -- Colorectal cancer patient advocacy groups, the American College of…
WASHINGTON, Aug. 15, 2016 /PRNewswire-USNewswire/ -- Colorectal cancer patient advocacy groups, the American College of…
WASHINGTON, Aug. 15, 2016 /PRNewswire-USNewswire/ -- Colorectal cancer patient advocacy groups, the American College of…
WASHINGTON, Aug. 15, 2016 /PRNewswire-USNewswire/ -- Colorectal cancer patient advocacy groups, the American College of…
WASHINGTON, Aug. 15, 2016 /PRNewswire-USNewswire/ -- Colorectal cancer patient advocacy groups, the American College of…
WASHINGTON, Aug. 15, 2016 /PRNewswire-USNewswire/ -- Colorectal cancer patient advocacy groups, the American College of…
WASHINGTON Recent United States Preventive Services Task Force (USPSTF) colorectal cancer (CRC) screening recommendations…
WASHINGTON, Aug. 15, 2016 /PRNewswire-USNewswire/ -- Colorectal cancer patient advocacy groups, the American College of…
07/26/2016 Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash utilization and gross…
This article originally appeared on FiveThirtyEight and is reprinted with permission.
Home » Top news Aug. 2, 2016—Epigenomics, the German-American cancer molecular diagnostics company, announced that the U.S.
Most Americans hear “colorectal cancer screening” and think “colonoscopy” — the unpleasant cleanse, the snakelike scope, the…
Yhdysvaltalaisasiantuntijat suosittavat paksu- ja peräsuolisyövän seulontoja kaikille 50–75-vuotiaille.
Jul 28, 2016 03:41 AM EDT Skin cancer screenings cannot reduce incidence of cancer deaths, a new study found.
Jul 28, 2016 03:41 AM EDT Skin cancer screenings cannot reduce incidence of cancer deaths, a new study found.
Jul 28, 2016 03:41 AM EDT Health experts have long since urged patients to undergo full-body screenings for possible…
While investors cheered EXACT Sciences Corporation's (NASDAQ: EXAS ) second-quarter results, sending shares up over 30% during…
/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $21.2 million during…
EXAS beat analyst revenue and profit expectations. They are in talks with insurers given the recent changes in the USPSTF…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
MADISON, Wis., July 26, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…
SOURCE EXACT SCIENCES CORP Revenues top $21 million, growing 161 percent year-over-year, 43 percent sequentially Cash…